Progesterone USP Recalled for Lack of Stability Data and Controls
American Pharmaceutical Ingredients LLC is recalling Progesterone USP for prescription compounding due to CGMP deviations involving missing stability data and controls.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically indicates a situation where use of the product could cause temporary or medically reversible health consequences. The specific hazard is a CGMP deviation regarding stability data, which is a quality control issue rather than a direct contamination or acute injury risk, fitting the Moderate severity criteria for low-risk contamination or voluntary precautionary recalls.
Plain-English summary
American Pharmaceutical Ingredients LLC is recalling specific lots of Progesterone USP (Micronized) (Yam) for prescription compounding. The product is available in various package sizes, including 1g, 10g, 25g, 100g, 500g, 1000g, and 5000g, and is distributed nationwide within the USA. The total quantity involved is 1,050,000 g.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the manufacturer lacked the necessary stability data and controls to support the assigned retest or expiration dates for the product in its container/closure system. This deficiency raises concerns about the product's quality and safety over time.
Healthcare providers and pharmacies should stop using the affected lots and contact the recalling firm for instructions on return or disposal. Patients who have received prescriptions containing these specific lots should consult their healthcare provider for guidance.
The recalled product
- Product
- Progesterone USP (Micronized) (Yam) for prescription compounding, packaged in a) 1g (NDC 58597-8471-1); b) 10g (NDC 58597-8471-3); c) 25g (NDC 58597-8471-4); d) 100g (NDC 58597-8471-6); e) 500g (NDC 58597-8471-7); f) 1000g (NDC 58597-8471-8); g) 5000g (NDC 58597-8471-9), RX only
- Manufacturer
- American Pharmaceutical Ingredients LLC
- Category
- Drug — Pharmaceutical Ingredient
- Affected units
- 1,050,000
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: a) 031115-3
- Exp. 12/24/2019
- b) 031115-3
- Exp. 12/24/2019 c) 031115-3
- 050815-3
- Exp. 04/14/2020
- d) 010716-1
- 010716-6
- Exp. 11/10/2018
- 030116-4
- Exp. 12/04/2018
- 031115-2
- 060116-9
- Exp. 4/28/2019
- 080416-1
- 080416-4
- Exp. 06/05/2019
- 080615-4
- Exp. 07/29/2020
- 112015-6
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 66 recalled by American Pharmaceutical Ingredients LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 66 products in this recall →Related recalls
Same manufacturer · American Pharmaceutical Ingredients LLC
See all →- ModerateAmerican Pharmaceutical Ingredients Recalls Sermorelin Acetate Powder Due to Stability Data
FDA (Drugs) · 2018-03-21
- ModerateOxytocin USP Powder Recalled Due to Insufficient Stability Data
FDA (Drugs) · 2018-03-21
- ModerateFDA Recalls Testosterone Cypionate Due to Missing Stability Data
FDA (Drugs) · 2018-02-28
- ModerateLevofloxacin Hemihydrate Recalled for Lack of Stability Data
FDA (Drugs) · 2018-02-28
- ModerateFDA Recalls Doxycycline Hyclate Due to Missing Stability Data
FDA (Drugs) · 2018-02-28
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19